Title |
Improving the cost-effectiveness of cardiovascular disease prevention in Australia: a modelling study
|
---|---|
Published in |
BMC Public Health, June 2012
|
DOI | 10.1186/1471-2458-12-398 |
Pubmed ID | |
Authors |
Linda J Cobiac, Anne Magnus, Jan J Barendregt, Rob Carter, Theo Vos |
Abstract |
Cardiovascular disease is the leading cause of death worldwide. Like many countries, Australia is currently changing its guidelines for cardiovascular disease prevention from drug treatment for everyone with 'high blood pressure' or 'high cholesterol', to prevention based on a patient's absolute risk. In this research, we model cost-effectiveness of cardiovascular disease prevention with blood pressure and lipid drugs in Australia under three different scenarios: (1) the true current practice in Australia; (2) prevention as intended under the current guidelines; and (3) prevention according to proposed absolute risk levels. We consider the implications of changing to absolute risk-based cardiovascular disease prevention, for the health of the Australian people and for Government health sector expenditure over the long term. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Canada | 1 | 33% |
United Kingdom | 1 | 33% |
Unknown | 1 | 33% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Malaysia | 1 | 1% |
United Kingdom | 1 | 1% |
Unknown | 95 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 14 | 14% |
Student > Master | 14 | 14% |
Student > Bachelor | 10 | 10% |
Other | 10 | 10% |
Student > Ph. D. Student | 9 | 9% |
Other | 20 | 21% |
Unknown | 20 | 21% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 32 | 33% |
Nursing and Health Professions | 10 | 10% |
Economics, Econometrics and Finance | 6 | 6% |
Social Sciences | 5 | 5% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 4% |
Other | 12 | 12% |
Unknown | 28 | 29% |